



Publication of the 2021 financial calendar

Euronext: MEDCL • Montpellier - France • February 1, 2021 - 5:45 pm CET

MedinCell today published its indicative financial calendar for the year 2021.

Event	Date*
Annual results 2020-2021 (April 2020-March 2021)	Wednesday, June 16, 2021
General Meeting	Friday, September 10, 2021
Half-Year results 2021-2022 (April-September 2021)	Wednesday, December 8, 2021

**subject to modification. Publication after financial markets close.*

About MedinCell

MedinCell is a clinical stage pharmaceutical company that develops a portfolio of long-acting injectable products in various therapeutic areas by combining its proprietary BEPO® technology with active ingredients already known and marketed. Through the controlled and extended release of the active pharmaceutical ingredient, MedinCell makes medical treatments more efficient, particularly thanks to improved compliance, i.e. compliance with medical prescriptions, and to a significant reduction in the quantity of medication required as part of a one-off or chronic treatment. The BEPO® technology makes it possible to control and guarantee the regular delivery of a drug at the optimal therapeutic dose for several days, weeks or months starting from the subcutaneous or local injection of a simple deposit of a few millimeters, fully bioresorbable. Based in Montpellier, MedinCell currently employs more than 130 people representing over 25 different nationalities.

Contacts

MedinCell
David Heuze
Communication leader
david.heuze@medincell.com
+33 (0)6 83 25 21 86

NewCap
Mathilde Bohin / Louis-Victor Delouvrier
Investor relations
medincell@newcap.eu
+33 (0)1 44 71 98 53

NewCap
Nicolas Merigeau
Media relations
medincell@newcap.eu
+33 (0)1 44 71 94 98